Amid drug shortages and recalls, at least 3 sellers of a widely used blood-pressure medication, valsartan, have raised prices since a series of safety-related recalls of the drug by other manufacturers; the FDA is attempting to conserve dwindling resources during the government shutdown by prioritizing drug applications; researchers are looking into a possible link between prescription opioids and a birth defect called gastroschisis.
Amid drug shortages and recalls, at least 3 sellers of a widely used blood-pressure medication, valsartan, have raised prices since a series of safety-related recalls of the drug by other manufacturers, The Wall Street Journal reported. In addition, of the nearly 120 drugs listed by the FDA as currently or recently in shortage, about one-third had price increases after the shortages started, according to the paper’s review of pricing data provided by RELX Group’s Elsevier health-information unit.The FDA is attempting to conserve dwindling resources during the government shutdown by prioritizing drug applications, The Washington Post reported. Commissioner Scott Gottlieb, MD, told the paper that the measures will only help preserve funds for a few weeks, and not months, if the shutdown is protracted. The 2018 fees are expected to run out about February 8, and the agency isn’t allowed to collect the 2019 fees during the shutdown, although it can shift funds from other activities.Researchers are looking into a possible link between prescription opioids and a birth defect called gastroschisis, the Associated Press reported. The condition causes an infant to be born with its intestines outside the stomach due to a hole in the abdominal wall. Most are repaired through surgery. Roughly 1800 such cases happen annually, but the number has been rising and officials don't know why.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More